drugset

drugset / Trial / NCT06668792

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

NCT06668792 ↗

Phase 2 Recruiting 100 enrolled Biocad

NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.

Timeline

Start: 2024-12-26
Primary completion: 2026-02
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCD-248	Unknown	—	Subcutaneous

Indications